Update on Management Recommendations for Advanced Cutaneous Squamous Cell Carcinoma
- PMID: 35158897
- PMCID: PMC8833756
- DOI: 10.3390/cancers14030629
Update on Management Recommendations for Advanced Cutaneous Squamous Cell Carcinoma
Abstract
Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer, the incidence of which has risen over the last years. Although cSCC rarely metastasizes, early detection and treatment of primary tumours are critical to limit progression and local invasion. Several prognostic factors related to patients' clinicopathologic profile and tumour features have been identified as high-risk markers and included in the stratification scales, but their association with regional control or survival is uncertain. Therefore, decision-making on the diagnosis and management of cSCC should be made based on each individual patient's characteristics. Recent advances in non-invasive imaging techniques and molecular testing have enhanced clinical diagnostic accuracy. Surgical excision is the mainstay of local treatment, whereas radiotherapy (RT) is recommended for patients with inoperable disease or in specific circumstances. Novel systemic treatments including immunotherapies and targeted therapies have changed the therapeutic landscape for cSCC. The anti-PD-1 agent cemiplimab is currently the only FDA/EMA-approved first-line therapy for patients with locally advanced or metastatic cSCC who are not candidates for curative surgery or RT. Given the likelihood of recurrence and the increased risk of developing multiple cSCC, close follow-up should be performed during the first years of treatment and continued long-term surveillance is warranted.
Keywords: cutaneous squamous cell carcinoma; multidisciplinary management; prognosis; surgery; systemic therapy.
Conflict of interest statement
J. Garcia-Foncillas discloses consulting/advisory/honoraria speaker roles with Abbott, Amgen, Astellas, Astra Zeneca, Biocartis, Boehringer Ingelheim, BMS, Bayer, Celgene, Eisai, Foundation Medicine, GSK, Hospira, Janssen, Lilly, Merck Serono, MSD, Novartis, Pharmamar, Pfizer, Roche, Sanofi, Servier, Sysmex, and Tesaro. R. Mesía discloses consulting/advisory/honoraria speaker role with Amgen, BMS, Merck Serono, MSD, Roche, and Sanofi. O. Sanmartín discloses consulting/advisory/honoraria speaker role with Roche, ISDIN, and Sanofi. F. Rojo has received honorary for consultancy from Roche, BMS, MSD, Merck, Novartis, Pfizer, Astra Zeneca, Abbvie, Pierre Fabre, InCyte, and Bayer. J. Mestre discloses consulting/advisory/honoraria speaker roles with Lavigor, Roche, and Sanofi. A. Tejera has received honoraria for consultancy from Sanofi. S. Martín discloses consulting/advisory/honoraria speaker roles with MSD, Sanofi/Regeneron, BMS, Novartis, Roche, and Pierre-Fabre. I. Azinovic discloses no conflicts of interest. The funder had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Figures



Similar articles
-
European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment.Eur J Cancer. 2020 Mar;128:83-102. doi: 10.1016/j.ejca.2020.01.008. Epub 2020 Feb 26. Eur J Cancer. 2020. PMID: 32113942
-
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment-Update 2023.Eur J Cancer. 2023 Nov;193:113252. doi: 10.1016/j.ejca.2023.113252. Epub 2023 Jul 28. Eur J Cancer. 2023. PMID: 37708630
-
Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline.Eur J Cancer. 2015 Sep;51(14):1989-2007. doi: 10.1016/j.ejca.2015.06.110. Epub 2015 Jul 25. Eur J Cancer. 2015. PMID: 26219687 Review.
-
Response of advanced cutaneous squamous cell carcinoma to immunotherapy: case report.Stem Cell Investig. 2021 Sep 6;8:19. doi: 10.21037/sci-2020-071. eCollection 2021. Stem Cell Investig. 2021. PMID: 34631872 Free PMC article.
-
Multidisciplinary management of locally advanced and metastatic cutaneous squamous cell carcinoma.Curr Oncol. 2020 Aug;27(4):e399-e407. doi: 10.3747/co.27.6015. Epub 2020 Aug 1. Curr Oncol. 2020. PMID: 32905333 Free PMC article. Review.
Cited by
-
Molecular targeted therapies for cutaneous squamous cell carcinoma: recent developments and clinical implications.EXCLI J. 2024 Feb 27;23:300-334. doi: 10.17179/excli2023-6489. eCollection 2024. EXCLI J. 2024. PMID: 38655092 Free PMC article. Review.
-
The Immunomodulatory Potential of Concurrent High-Dose Radiotherapy and Immune Checkpoint Inhibitor Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma: Initial Results.J Pers Med. 2024 May 29;14(6):581. doi: 10.3390/jpm14060581. J Pers Med. 2024. PMID: 38929802 Free PMC article.
-
Survival After Orbital Exenteration for Primary Cutaneous Squamous Cell Carcinoma: A Retrospective Cohort Study.Ann Surg Oncol. 2025 Apr;32(4):2725-2731. doi: 10.1245/s10434-024-16854-w. Epub 2025 Jan 13. Ann Surg Oncol. 2025. PMID: 39806049 Free PMC article.
-
Involvement of necroptosis in the selective toxicity of the natural compound (±) gossypol on squamous skin cancer cells in vitro.Arch Toxicol. 2023 Jul;97(7):1997-2014. doi: 10.1007/s00204-023-03516-1. Epub 2023 May 21. Arch Toxicol. 2023. PMID: 37210688 Free PMC article.
-
Pigmented Superficial Basal Cell Carcinoma of the Nipple-Areola Complex: A Case Report.Case Rep Dermatol. 2025 Jan 16;17(1):19-25. doi: 10.1159/000542168. eCollection 2025 Jan-Dec. Case Rep Dermatol. 2025. PMID: 39822933 Free PMC article.
References
-
- Tejera-Vaquerizo A., Descalzo-Gallego M.A., Otero-Rivas M.M., Posada-García C., Rodríguez-Pazos L., Pastushenko I., Marcos-Gragera R., García-Doval I. Skin Cancer Incidence and Mortality in Spain: A Systematic Review and Meta-Analysis. Actas Dermosifiliogr. 2016;107:318–328. doi: 10.1016/j.ad.2015.12.008. - DOI - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials